News
11-18-2011, 09:42 PM
Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.
More... (http://www.news-medical.net/news/20111118/FDA-Commissioner-revokes-approval-of-Genentechs-Avastin-for-treatment-of-mBC.aspx)
More... (http://www.news-medical.net/news/20111118/FDA-Commissioner-revokes-approval-of-Genentechs-Avastin-for-treatment-of-mBC.aspx)